. 2021 Jan 14;11:1365. doi: 10.1038/s41598-020-80523-7

Table 5.

Risk factors for ICC in PS matched cohort.

	Univariate analysis				Multivariate analysis
	HR	95% CI		P-value	HR	95% CI		P-value
Main model
Tenofovir (ref: Entecavir)	0.92	0.28	2.99	0.890	0.94	0.29	3.07	0.914
Age, y/o	1.10	1.05	1.16	< 0.001	1.09	1.04	1.15	0.001
Male (ref: Female)	2.70	0.60	12.08	0.194	2.94	0.65	13.23	0.160
Liver Cirrhosis (ref: without)	6.27	1.40	28.01	0.016	3.59	0.78	16.42	0.100
DM (ref: without)	2.69	0.90	8.04	0.077	1.54	0.50	4.72	0.449
Covariates
Platelet^a	0.996	0.988	1.004	0.297	1.004	0.996	1.012	0.365
AFP^a	0.999	0.989	1.008	0.790	0.998	0.986	1.010	0.763
Albumin^a	0.60	0.29	1.24	0.167	0.80	0.36	1.77	0.585
Bilirubin^a	0.95	0.75	1.19	0.643	0.91	0.67	1.23	0.530
INR^a	2.00	0.63	6.30	0.237	1.73	0.43	6.93	0.436
FIB-4^a	1.14	0.93	1.39	0.223	1.12	0.88	1.42	0.353
APRI^a	1.05	1.02	1.08	< 0.001	1.04	1.00	1.09	0.044

PS propensity score, HR hazard ratio, CT confidence interval, DM diabetes mellitus, AFP alpha-fetoprotein, INR international normalized ratio, FIB-4 fibrosis index based on 4 factors, APRI AST to platelet ratio index.

^aAdjusted for tenofovir, sex, age, liver cirrhosis, DM.